Boston reaches enrolment target in TAXUS IV trial:
This article was originally published in Clinica
Boston Scientific is making progress with its bid to market its paclitaxel-eluting stent in the US, after completing an important enrolment phase of a pivotal trial designed to support regulatory filings for the product. Some 1,172 patients have been enrolled in the TAXUS IV trial - the target number for the study. The patients have received stents of 16mm and 24mm in length and their progress is now being followed. Additional patients requiring 32mm stents are also being enrolled in the study to satisfy a portion of the trial's clinical protocol.